It is recommended that Multiple Sclerosis Natalizumab treatment be reserved as an option only for cases of rapidly evolving severe relapsing–remitting multiple sclerosis or (RES). RES is defined as two or more debilitating relapses in a year, and one or more gadolinium-enhancing lesions on a brain MRI.

MS Natalizumab therapy is given by intravenous injection and the dose is 300 mg every 28 days.  Monitoring for symptoms of immunogenicity and hypersensitivity is required and recommended.  Multiple Sclerosis Natalizumab therapy has statistically reduced the probability of disability progression compared with placebo groups in both ITT and RES patient trials.  In addition, MS Natalizumab treatment led to a reduction in the relapse rate, with a risk reduction of 0.68 in the ITT patients and 0.81 in the RES patients. The manufacturer also showed evidence that, compared with placebo, MS Natalizumab infusions significantly improved health-related quality of life.  And since MS doesn’t necessarily …